Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in moderately to severely active systemic lupus erythematosus
NCT05306574Phase 3Terminated
- Sponsor
- Vor Bio
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Vor Bio. Started Jun 2022; status: terminated.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05306574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306574.